knowledge -WSS

knowledge

author：knowledge 2025-09-30 00:37:31 - browse：9

Photograph of Bill Cassidy. -- health policy coverage from STAT — Sen. Bill Cassidy (R-La.) Kevin Dietsch/Getty Images

WASHINGTON — With Novo Nordisk’s Wegovy and Ozempic hitting blockbuster sales and a new rival approved this week, everyone in Washington is thinking about how to manage the crashing wave of weight loss drug costs.

The explosive national demand for weight management therapies and diabetes drugs like Ozempic — all of which are indicated for indefinite use — has become central in an ongoing policy debate over high drug costs and controversial tactics to manage them, including President Biden’s plan to let the government negotiate directly with pharmaceutical companies. Seventy percent of Americans could qualify for these medicines.

Sen. Bill Cassidy (R-La.), the highest-ranking Republican on the Senate’s health policy committee, has vehemently opposed the negotiation plan, arguing it reduces incentives to develop new therapies and may not actually reduce patients’ costs.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Addiction doctors spar with methadone clinics over legislation

WSS

David Sabatini, ex

Akili, maker of video game for ADHD, to be acquired for 34 million

Male doctors called my cancer incurable. A female doctor showed it wasn't

Hospital chaplains balance Covid safety with patients’ spiritual needs

Stigma and the return of syphilis

Antibiotic resistance nearly killed me, so I'm raising awareness of it

knowledge

knowledge

knowledge

Trump demands the U.S. pay no more for drugs than other countries … again

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Apple is now the first public company to be valued at $3 trillion

Arena BioWorks launches in Cambridge to speed drug discovery

Medical leaders decry Supreme Court decision on affirmative action

Do more moles mean more problems? Not so, says new study

As demand for Covid shots wanes, Moderna seeks its next success

Medicare Advantage coverage denials need scrutiny, senators say

Malaria cases in Florida and Texas: Here’s what you need to know

JPM pitch from hospitals? Revenue streams outside of patient care

focus

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

Heat waves linked to early deliveries, preterm births in new study

Life science postdocs should get big pay hike, NIH panel says

Physician assistants need a new name. Here's what it should be

Scientists successfully use ultrasound imaging to map brain activity

Insmed lung disease drug hits target in key Phase 3 trial

hotspot

hotspot

knowledge

explore